<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01788215</url>
  </required_header>
  <id_info>
    <org_study_id>RSRB 00034479</org_study_id>
    <nct_id>NCT01788215</nct_id>
  </id_info>
  <brief_title>Effect of a Commonly Used Antibiotic, Doxycycline, in Women With Polycystic Ovarian Syndrome</brief_title>
  <acronym>MI-PCOS</acronym>
  <official_title>The Use of an MMP Inhibitor, Doxycycline, to Reduce Ovarian Androgen Production and Restore Normal Cycling in Women With Polycystic Ovarian Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the effect of a commonly used antibiotic, doxycycline,
      on the production of ovarian hormones and menstrual cycles in women with Polycystic Ovarian
      Syndrome (PCOS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polycystic ovarian syndrome (PCOS) is one of the leading causes of female infertility,
      affecting 5-10% of reproductive-age women . This heterogeneous disorder is characterized by
      anovulatory infertility, androgen excess, an increase in the ratio of LH to FSH, and
      morphologic polycystic changes to the ovaries. Obesity and insulin resistance are also
      metabolic factors associated with PCOS that further increase the morbidity in these patients.
      Inducing fertility in patients with PCOS can be a challenge, as it most often involves
      ovulation induction that can lead to ovarian enlargement, hyperstimulation, and
      multiple-birth pregnancies. This study is designed to determine novel effective strategies to
      promote normal cycling in this patient population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Serum Testosterone</measure>
    <time_frame>24 weeks</time_frame>
    <description>We will determine total serum testosterone levels in all participating subjects at week 24.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Serum Testosterone</measure>
    <time_frame>week 12</time_frame>
    <description>We will determine total serum testosterone levels in all participating subjects at week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Progesterone Levels in Blood</measure>
    <time_frame>24 weeks</time_frame>
    <description>Serum progesterone levels will be obtained on a weekly basis to assess ovulation. We will then perform statistical analysis on this data to determine the effectiveness of doxycycline in this study population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free Testosterone in Serum</measure>
    <time_frame>week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free Testosterone in Serum</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Hormone Binding Globulin (SHBG)</measure>
    <time_frame>week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Hormone Binding Globulin (SHBG)</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Ovulations</measure>
    <time_frame>week 24</time_frame>
    <description>The total number of ovulations per group. Ovulation was defined as elevation of serum progesterone and or urinary pregnanediol glucuronide followed by documented menstrual bleeding within 2 weeks of elevation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Polycystic Ovarian Syndrome (PCOS)</condition>
  <condition>Irregular Menstrual Cycles</condition>
  <condition>Androgen Excess</condition>
  <arm_group>
    <arm_group_label>Doxycycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to receive doxycycline for a period of 12 weeks. A 12-week period thereafter will occur off study medication. The dose of doxycycline to be used in this study is 200mg/day in divided doses of 100mg twice daily. The dose of doxycycline being used in this study is 100mg because it is the standard approved dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The administered placebo is to be continued for a period of 12 weeks. A 12-week period thereafter will occur off placebo control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxycycline</intervention_name>
    <description>200mg/day in divided doses of 100mg twice daily</description>
    <arm_group_label>Doxycycline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sugar Pill</intervention_name>
    <description>1 pill twice a day</description>
    <arm_group_label>Sugar Pill</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women between 18 and 40 years of age.

          2. History of PCOS with &lt; 8 periods the proceeding year

          3. Clinical or biochemical evidence of androgen excess

          4. BMI &lt;40

          5. Willingness to sign consent for study including participation with collection of blood
             specimens

          6. Willingness to discontinue OCP for duration of study period up to 36 weeks

        Exclusion Criteria:

          1. Pregnancy

          2. Hypersensitivity to doxycycline or tetracycline

          3. History of Cushing's syndrome

          4. History of hyperprolactinemia

          5. History of congenital adrenal hyperplasia

          6. Significant hepatic impairment, including serum AST or ALT &gt;1.5 times upper limits of
             normal.

          7. Significant renal impairment, GFR &lt;60 ml/min

          8. Current use of metformin, statins, glucocorticoids, spironolactone and/or
             anti-estrogens.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen M Hoeger, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Hammes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester, Strong Fertility Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2011</study_first_submitted>
  <study_first_submitted_qc>February 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2013</study_first_posted>
  <results_first_submitted>October 23, 2015</results_first_submitted>
  <results_first_submitted_qc>December 9, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 13, 2016</results_first_posted>
  <last_update_submitted>December 9, 2015</last_update_submitted>
  <last_update_submitted_qc>December 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Kathleen M. Hoeger, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Polycystic Ovarian Syndrome</keyword>
  <keyword>Irregular Menstrual Cycles</keyword>
  <keyword>Androgen Excess in Women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Hyperandrogenism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>13 women were recruited. 3 did not meet inclusion/esclusion criteria.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Doxycycline</title>
          <description>Subjects randomized to receive doxycycline for a period of 12 weeks. A 12-week period thereafter will occur off study medication. The dose of doxycycline to be used in this study is 200mg/day in divided doses of 100mg twice daily. The dose of doxycycline being used in this study is 100mg because it is the standard approved dose.
doxycycline: 200mg/day in divided doses of 100mg twice daily</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill</title>
          <description>The administered placebo is to be continued for a period of 12 weeks. A 12-week period thereafter will occur off placebo control
Sugar Pill: 1 pill twice a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>12 Weeks of Doxycycline or Placebo</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Doxycycline</title>
          <description>Subjects randomized to receive doxycycline for a period of 12 weeks. A 12-week period thereafter will occur off study medication. The dose of doxycycline to be used in this study is 200mg/day in divided doses of 100mg twice daily. The dose of doxycycline being used in this study is 100mg because it is the standard approved dose.
doxycycline: 200mg/day in divided doses of 100mg twice daily</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill</title>
          <description>The administered placebo is to be continued for a period of 12 weeks. A 12-week period thereafter will occur off placebo control
Sugar Pill: 1 pill twice a day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>total serum testosterone</title>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.6" spread="8.2"/>
                    <measurement group_id="B2" value="49.6" spread="8.2"/>
                    <measurement group_id="B3" value="50.1" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>free serum testosterone</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.14" spread="0.57"/>
                    <measurement group_id="B2" value="1.36" spread="0.39"/>
                    <measurement group_id="B3" value="1.25" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>serum hormone binding globulin (SHBG)</title>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.0" spread="13.2"/>
                    <measurement group_id="B2" value="44.0" spread="13.5"/>
                    <measurement group_id="B3" value="49.5" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Serum Testosterone</title>
        <description>We will determine total serum testosterone levels in all participating subjects at week 24.</description>
        <time_frame>24 weeks</time_frame>
        <population>in the sugar pill arm one participant dropped out at week 12</population>
        <group_list>
          <group group_id="O1">
            <title>Doxycycline</title>
            <description>Subjects randomized to receive doxycycline for a period of 12 weeks. A 12-week period thereafter will occur off study medication. The dose of doxycycline to be used in this study is 200mg/day in divided doses of 100mg twice daily. The dose of doxycycline being used in this study is 100mg because it is the standard approved dose.
doxycycline: 200mg/day in divided doses of 100mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>The administered placebo is to be continued for a period of 12 weeks. A 12-week period thereafter will occur off placebo control
Sugar Pill: 1 pill twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Total Serum Testosterone</title>
          <description>We will determine total serum testosterone levels in all participating subjects at week 24.</description>
          <population>in the sugar pill arm one participant dropped out at week 12</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.8" spread="13.6"/>
                    <measurement group_id="O2" value="41.6" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Progesterone Levels in Blood</title>
        <description>Serum progesterone levels will be obtained on a weekly basis to assess ovulation. We will then perform statistical analysis on this data to determine the effectiveness of doxycycline in this study population.</description>
        <time_frame>24 weeks</time_frame>
        <population>This measurement was not completed, because the number of ovulations was measured in its place and better indicates the effect of the treatment. See outcome measure number 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Doxycycline</title>
            <description>Subjects randomized to receive doxycycline for a period of 12 weeks. A 12-week period thereafter will occur off study medication. The dose of doxycycline to be used in this study is 200mg/day in divided doses of 100mg twice daily. The dose of doxycycline being used in this study is 100mg because it is the standard approved dose.
doxycycline: 200mg/day in divided doses of 100mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>The administered placebo is to be continued for a period of 12 weeks. A 12-week period thereafter will occur off placebo control
Sugar Pill: 1 pill twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Progesterone Levels in Blood</title>
          <description>Serum progesterone levels will be obtained on a weekly basis to assess ovulation. We will then perform statistical analysis on this data to determine the effectiveness of doxycycline in this study population.</description>
          <population>This measurement was not completed, because the number of ovulations was measured in its place and better indicates the effect of the treatment. See outcome measure number 8.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Serum Testosterone</title>
        <description>We will determine total serum testosterone levels in all participating subjects at week 12.</description>
        <time_frame>week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Doxycycline</title>
            <description>Subjects randomized to receive doxycycline for a period of 12 weeks. A 12-week period thereafter will occur off study medication. The dose of doxycycline to be used in this study is 200mg/day in divided doses of 100mg twice daily. The dose of doxycycline being used in this study is 100mg because it is the standard approved dose.
doxycycline: 200mg/day in divided doses of 100mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>The administered placebo is to be continued for a period of 12 weeks. A 12-week period thereafter will occur off placebo control
Sugar Pill: 1 pill twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Total Serum Testosterone</title>
          <description>We will determine total serum testosterone levels in all participating subjects at week 12.</description>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.4" spread="10.8"/>
                    <measurement group_id="O2" value="43.0" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Free Testosterone in Serum</title>
        <time_frame>week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Doxycycline</title>
            <description>Subjects randomized to receive doxycycline for a period of 12 weeks. A 12-week period thereafter will occur off study medication. The dose of doxycycline to be used in this study is 200mg/day in divided doses of 100mg twice daily. The dose of doxycycline being used in this study is 100mg because it is the standard approved dose.
doxycycline: 200mg/day in divided doses of 100mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>The administered placebo is to be continued for a period of 12 weeks. A 12-week period thereafter will occur off placebo control
Sugar Pill: 1 pill twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Free Testosterone in Serum</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="0.39"/>
                    <measurement group_id="O2" value="1.16" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Free Testosterone in Serum</title>
        <time_frame>week 24</time_frame>
        <population>in the sugar till arm, one participant dropped out at week 12</population>
        <group_list>
          <group group_id="O1">
            <title>Doxycycline</title>
            <description>Subjects randomized to receive doxycycline for a period of 12 weeks. A 12-week period thereafter will occur off study medication. The dose of doxycycline to be used in this study is 200mg/day in divided doses of 100mg twice daily. The dose of doxycycline being used in this study is 100mg because it is the standard approved dose.
doxycycline: 200mg/day in divided doses of 100mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>The administered placebo is to be continued for a period of 12 weeks. A 12-week period thereafter will occur off placebo control
Sugar Pill: 1 pill twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Free Testosterone in Serum</title>
          <population>in the sugar till arm, one participant dropped out at week 12</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="1.56"/>
                    <measurement group_id="O2" value="1.08" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Hormone Binding Globulin (SHBG)</title>
        <time_frame>week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Doxycycline</title>
            <description>Subjects randomized to receive doxycycline for a period of 12 weeks. A 12-week period thereafter will occur off study medication. The dose of doxycycline to be used in this study is 200mg/day in divided doses of 100mg twice daily. The dose of doxycycline being used in this study is 100mg because it is the standard approved dose.
doxycycline: 200mg/day in divided doses of 100mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>The administered placebo is to be continued for a period of 12 weeks. A 12-week period thereafter will occur off placebo control
Sugar Pill: 1 pill twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Hormone Binding Globulin (SHBG)</title>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.4" spread="12.4"/>
                    <measurement group_id="O2" value="39.4" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Hormone Binding Globulin (SHBG)</title>
        <time_frame>week 24</time_frame>
        <population>in the sugar pill arm, one participant withdrew at week 12</population>
        <group_list>
          <group group_id="O1">
            <title>Doxycycline</title>
            <description>Subjects randomized to receive doxycycline for a period of 12 weeks. A 12-week period thereafter will occur off study medication. The dose of doxycycline to be used in this study is 200mg/day in divided doses of 100mg twice daily. The dose of doxycycline being used in this study is 100mg because it is the standard approved dose.
doxycycline: 200mg/day in divided doses of 100mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>The administered placebo is to be continued for a period of 12 weeks. A 12-week period thereafter will occur off placebo control
Sugar Pill: 1 pill twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Hormone Binding Globulin (SHBG)</title>
          <population>in the sugar pill arm, one participant withdrew at week 12</population>
          <units>nmol /L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.8" spread="10.6"/>
                    <measurement group_id="O2" value="36.2" spread="6.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Ovulations</title>
        <description>The total number of ovulations per group. Ovulation was defined as elevation of serum progesterone and or urinary pregnanediol glucuronide followed by documented menstrual bleeding within 2 weeks of elevation.</description>
        <time_frame>week 24</time_frame>
        <population>In the sugar pill arm, one participant withdrew at week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Doxycycline</title>
            <description>Subjects randomized to receive doxycycline for a period of 12 weeks. A 12-week period thereafter will occur off study medication. The dose of doxycycline to be used in this study is 200mg/day in divided doses of 100mg twice daily. The dose of doxycycline being used in this study is 100mg because it is the standard approved dose.
doxycycline: 200mg/day in divided doses of 100mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>The administered placebo is to be continued for a period of 12 weeks. A 12-week period thereafter will occur off placebo control
Sugar Pill: 1 pill twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Ovulations</title>
          <description>The total number of ovulations per group. Ovulation was defined as elevation of serum progesterone and or urinary pregnanediol glucuronide followed by documented menstrual bleeding within 2 weeks of elevation.</description>
          <population>In the sugar pill arm, one participant withdrew at week 12.</population>
          <units>ovulations</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Doxycycline</title>
          <description>Subjects randomized to receive doxycycline for a period of 12 weeks. A 12-week period thereafter will occur off study medication. The dose of doxycycline to be used in this study is 200mg/day in divided doses of 100mg twice daily. The dose of doxycycline being used in this study is 100mg because it is the standard approved dose.
doxycycline: 200mg/day in divided doses of 100mg twice daily</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill</title>
          <description>The administered placebo is to be continued for a period of 12 weeks. A 12-week period thereafter will occur off placebo control
Sugar Pill: 1 pill twice a day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was underpowered due to reduced enrollment. Targeted enrollment was 40 and actual enrollment was 10.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kathleen Hoeger MD MPH</name_or_title>
      <organization>University of Rochester</organization>
      <phone>585-275-7891</phone>
      <email>kathleen_hoeger@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

